Long-term safety of cenerimod in lupus patients
Part of Immune system & allergy, Skin clinical trials.
This study tests the long-term safety of a drug called cenerimod for people with lupus (SLE) who have already completed a 12-month study of the same drug. It helps researchers see if the medicine stays safe and tolerable over a longer period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have already taken part in one of two earlier studies (ID-064A301 or ID-064A302) and finished the full 12 months of treatment.
- You cannot have stopped the earlier study drug early for any reason.
- If you can become pregnant, you need a negative pregnancy test and must use highly effective birth control during the study and for 6 months after.
- You must not have severe lupus-related kidney or brain disease that needs stronger treatment than allowed in this study.
- You cannot have active or untreated tuberculosis (if local rules require testing).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if an investigational drug called cenerimod can safely and effectively treat active lupus nephritis when added to your regular lupus medications. It's for people with recent kidney biopsy showing active lupus kidney disease and high protein in urine.
This trial tests an investigational drug called AZD0120 in adults with lupus that hasn't improved with standard treatments. The goal is to see if it's safe and works well for people with lupus-related organ problems.
This trial tests whether sirolimus, a medication usually used to prevent organ transplant rejection, can help reduce lupus disease activity. If you have active lupus that isn't severe in your kidneys or brain, this could be a new treatment option.
This trial tests a new medicine, nipocalimab, for adults with moderate to severe lupus. It aims to see if the drug can help control lupus symptoms and reduce disease activity.
This study is a long-term follow-up of a drug called enpatoran. People who completed the earlier Elowen-1 or Elowen-2 studies can continue taking the drug to see if it keeps helping their lupus skin symptoms safely over time.
This extension study tests the long-term safety of ianalumab for people with systemic lupus erythematosus. If you completed a prior SIRIUS-SLE study and your doctor thinks you'd benefit, you may continue treatment for up to 60 more weeks.
Hear when a new Lupus Erythematosus, Systemic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.